We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 11, 2020

Olaparib Plus Durvalumab in Recurrent Ovarian Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: A Proof-of-Concept Phase II Study
Clin. Cancer Res 2020 Jul 01;[EPub Ahead of Print], EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, EM Swisher, JW Hodge, AB Nixon, E Nichols, MH Bagheri, E Levy, MR Radke, S Lipkowitz, CM Annunziata, JM Taube, SM Steinberg, JM Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading